This Is a Neuron on Nicotine

When a person takes a puff on a cigarette, nicotine floods into the brain, latching onto receptors on the surface of neurons and producing feelings of happiness. But nicotine does not simply stay on the surface of cells - the drug actually permeates into neural cells and alters them from the inside out. Now, a team of scientists has developed a protein sensor that glows in the presence of nicotine, allowing the researchers to observe nicotine's movements in cells and reveal more about the nature of nicotine addiction.

The work was led by Henry Lester, professor of biology at Caltech and previously a visiting scientist at the Janelia Research Campus of the Howard Hughes Medical Institute (HHMI). A paper describing the research appears online on February 4 in the Journal of General Physiology. Lester is also an affiliated faculty member of the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech.

The endoplasmic reticulum is the equivalent of a cell's factory and warehouse--the place where proteins are synthesized and packaged in order to be shipped to various other locations both inside and outside of the cell. Nicotinic receptors (nAChRs) are among these proteins; after being manufactured in the endoplasmic reticulum, they then travel to the cell's surface. When nicotine molecules enter the body, they travel through the bloodstream and reach brain cells, where they meet the nAChRs on the surface of these cells. This triggers the cells' processes of releasing chemicals of reward and happiness.

What happens once nicotine has moved into the cells, however, has not been well understood. Lester and others previously found that some nAChRs remain in the "warehouse"--the endoplasmic reticulum--where they, too, can bind to nicotine. Hoping to gain insights into nicotine's effects within cells, Lester and his team developed a tool called a biosensor to visualize where the drug collects inside of cells. The biosensor is composed of a special protein that can open and close, like a Venus flytrap, and an inactivated fluorescent protein. The sensor is designed to close around nicotine, and this then activates the fluorescent protein to glow brightly, indicating where the nicotine molecules are located and how many are present.

Scientists can put the biosensors into particular parts of a cell - in this work, they placed them in the endoplasmic reticulum and on cells' surfaces - and watch them light up as nicotine floods in.

By making movies of cells containing biosensors in a lab dish, the team has discovered that nicotine enters into the endoplasmic reticulum within a few seconds of appearing outside a cell. Furthermore, the nicotine levels are more than enough to affect nAChRs during their assembly and to chaperone additional nAChRs on their journey to the cell surface. As a result, the neurons are more sensitive to the nicotine, which enhances the rewarding feelings after a puff on a tobacco cigarette or an e-cigarette. In other words, the more a person smokes, the more quickly and easily the smoker gets a nicotine buzz. This is part of nicotine addiction.

While the movies now focus on isolated neurons in the lab, the scientists want to determine whether nicotine's intracellular movements are similar in the neurons of live mice. Additionally, they are developing biosensors for other drugs, such as opioids and antidepressants, to observe how these compounds interact inside and outside of cells.

Amol V Shivange, Philip M Borden, Anand K Muthusamy, Aaron L Nichols, Kallol Bera, Huan Bao, Ishak Bishara, Janice Jeon, Matthew J Mulcahy, Bruce Cohen, Saidhbhe L O'Riordan, Charlene Kim, Dennis A Dougherty, Edwin R Chapman, Jonathan Marvin, Loren Looger, Henry A Lester.
Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors.
The Journal of General Physiology. Feb 2019. doi: 10.1085/jgp.201812201.

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...